Literature DB >> 29286924

Expression of CD105 cancer stem cell marker in three subtypes of renal cell carcinoma.

Leili Saeednejad Zanjani1, Zahra Madjd1,2, Maryam Abolhasani1,3, Ahmad Shariftabrizi4, Arezoo Rasti1, Mojgan Asgari1,3.   

Abstract

BACKGROUND: CD105 is recently described as a cancer stem cell (CSC) marker.
OBJECTIVE: The present study was aimed to investigate the expression and prognostic significance of the CSC marker CD105 in different histological subtypes of renal cell carcinoma (RCC).
METHODS: Expression of CD105 was evaluated using immunohistochemistry in RCC samples on tissue microarrays including clear cell RCCs (ccRCCs), papillary, and chromophobe RCCs. The association between CD105 expression and clinicopathological features as well as survival outcomes was determined.
RESULTS: In ccRCC, increased tumoral cytoplasmic and endothelial expression of CD105 were significantly associated with advanced stage, renal vein invasion, and microvascular invasion (MVI). In addition, MVI was associated with a worse overall survival (OS). Moreover, in multivariate analysis tumor stage and nuclear grade were independent prognostic factors for OS both in case of tumoral cytoplasmic and endothelial CD105 expression. Additionally, CD105 expression was found to be a predictor of worse OS in univariate analysis. However, in papillary and chromophobe RCC, no significant association was found between CD105 expression and clinicopathological parameters or prognosis.
CONCLUSIONS: We showed that CD105 expression was associated with more aggressive tumor behavior, more advanced disease, and worse prognosis in ccRCC but not in the other RCC subtypes.

Entities:  

Keywords:  CD105; RCC subtypes; cancer stem cells (CSCs); endothelial expression; renal cell carcinoma (RCC); tissue microarray (TMA)

Mesh:

Substances:

Year:  2018        PMID: 29286924     DOI: 10.3233/CBM-170755

Source DB:  PubMed          Journal:  Cancer Biomark        ISSN: 1574-0153            Impact factor:   4.388


  6 in total

1.  Spheroid culture models adequately imitate distinctive features of the renal cancer or melanoma microenvironment.

Authors:  Aleksandra Filipiak-Duliban; Klaudia Brodaczewska; Aleksandra Majewska; Claudine Kieda
Journal:  In Vitro Cell Dev Biol Anim       Date:  2022-05-10       Impact factor: 2.416

2.  Effect of resveratrol and oxyresveratrol on deferoxamine-induced cancer stem cell marker expression in human head and neck squamous cell carcinoma.

Authors:  Artid Amorntaveechai; Thanaphum Osathanon; Prasit Pavasant; Sireerat Sooampon
Journal:  J Oral Biol Craniofac Res       Date:  2022-03-16

Review 3.  CD105: tumor diagnosis, prognostic marker and future tumor therapeutic target.

Authors:  Lan Li; Liping Zhong; Chao Tang; Lu Gan; Tong Mo; Jintong Na; Jian He; Yong Huang
Journal:  Clin Transl Oncol       Date:  2022-02-15       Impact factor: 3.340

4.  ImmunoPET: Concept, Design, and Applications.

Authors:  Weijun Wei; Zachary T Rosenkrans; Jianjun Liu; Gang Huang; Quan-Yong Luo; Weibo Cai
Journal:  Chem Rev       Date:  2020-03-23       Impact factor: 60.622

5.  Microglial Phenotyping in Neurodegenerative Disease Brains: Identification of Reactive Microglia with an Antibody to Variant of CD105/Endoglin.

Authors:  Douglas G Walker; Lih-Fen Lue; Thomas G Beach; Ikuo Tooyama
Journal:  Cells       Date:  2019-07-23       Impact factor: 6.600

6.  Renal carcinoma CD105-/CD44- cells display stem-like properties in vitro and form aggressive tumors in vivo.

Authors:  M Fiedorowicz; M I Khan; D Strzemecki; J Orzeł; M Wełniak-Kamińska; A Sobiborowicz; M Wieteska; Z Rogulski; L Cheda; W Wargocka-Matuszewska; K Kilian; C Szczylik; A M Czarnecka
Journal:  Sci Rep       Date:  2020-03-25       Impact factor: 4.379

  6 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.